[
    [
        {
            "time": "",
            "original_text": "抗疫一周年公益再出发 复星医疗加快“硬核”科技打造健康管理平台",
            "features": {
                "keywords": [
                    "抗疫",
                    "复星医疗",
                    "硬核科技",
                    "健康管理平台"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医疗",
                    "健康科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "抗疫一周年公益再出发 复星医疗加快“硬核”科技打造健康管理平台",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2023-03-26",
            "original_text": "智通港股通持股分析 | 3月26日",
            "features": {
                "keywords": [
                    "港股通",
                    "持股分析"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "智通港股通持股分析 | 3月26日",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 3,
                "Market_Scope": 7,
                "Time_Proximity": 9,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "协和发酵麒麟布罗索尤单抗新适应证获批；和黄医药1.69亿美元出售非处方药合资企业；复星医药新冠疫苗暂停港澳地区接种",
            "features": {
                "keywords": [
                    "协和发酵麒麟",
                    "布罗索尤单抗",
                    "和黄医药",
                    "非处方药",
                    "复星医药",
                    "新冠疫苗",
                    "港澳地区"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "制药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "协和发酵麒麟布罗索尤单抗新适应证获批；和黄医药1.69亿美元出售非处方药合资企业；复星医药新冠疫苗暂停港澳地区接种",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        }
    ]
]